Journal
AMERICAN JOURNAL OF KIDNEY DISEASES
Volume 54, Issue 5, Pages 931-934Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ajkd.2009.03.013
Keywords
Deferasirox; Fanconi syndrome; iron; renal toxicity
Categories
Ask authors/readers for more resources
Deferasirox is an innovative iron-chelating treatment. However, preliminary data have suggested that kidney toxicity may be a major issue in the management of patients receiving this drug. We report a case of Fanconi syndrome associated with acute renal insufficiency in a patient receiving deferasirox. The latter has to be added to the expanding list of drugs that may induce Fanconi syndrome. Careful monitoring of kidney function and markers of proximal tubular injury are mandatory in patients undergoing treatment with deferasirox. Am J Kidney Dis 54:931-934. (C) 2009 by the National Kidney Foundation, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available